STAT3 phosphorylation has been detected in fibrotic lung tissue from IPF patients and participates in both the fibroblast to myofibroblast transition and lung epithelial cell damage; therefore, it is an attractive therapeutic target in IPF [11–13]. This evidence concerns the gene STAT3 and idiopathic pulmonary fibrosis.